Tata Capital Healthcare Fund II Addresses Healthcare Sector Gaps

·         Over the last year, health beneficiaries both direct and indirect totalled 9 million+ for the fund’s portfolio universe

·         6 out 7 of the current portfolio companies cater to 30% of India’s NCD (Non-communicable disease) disease burden in areas of cancer, neuropsychiatry and nephrology

Tata Capital Healthcare Fund II (TCHF II), the follow-on healthcare-focused private equity fund under Tata Capital Ltd, has concluded 7 investments to date. TCHF II has already allocated 60% of the USD 130Mn corpus raised last year. The fund is setting sights on additional investments in pharmaceutical manufacturing, pharmaceutical distribution and consumer nutrition among others. The fund expects to add 3 to 4 more investee companies by the middle of 2024.

The current TCHF II portfolio is strategically diversified across domestic and export pharmaceuticals, cancer care clinics, dialysis centers, integrated regional diagnostic chains, and digital healthcare. This has positioned the fund platform as an influential player in driving societal transformation and profitable growth. Each of these strategic investments are designed to address India’s disease burden as well as healthcare access, through effective and affordable healthcare solutions for the society at large.

Ms Visalakshi Chandramouli, Managing Partner at Tata Capital Healthcare Fund said, “Our Healthcare Fund is aimed to positively impact people, product and health enterprises. We strongly believe in a transformative approach, underpinned by our 3P framework—People, Process, and Performance. We're thrilled to report remarkable 9.3Mn health beneficiaries both direct and indirect in FY23, 44 new jobs created with $1Mn invested by the fund and a 35% uptick in women employees across our portfolio companies”.